KRAS and lung carcinoma: Furthermore, shRNA targeting of KRAS prevented the TNF-ɑ hyperstimulation of NF-κB transcriptional activity in the A549 human lung cancer cell line, as measured by the abundance of its transcriptional targets COX2, ICAM1, and A20 (Tago et al., 2019).